75 reports of this reaction
1.6% of all PROPAFENONE HYDROCHLORIDE reports
#14 most reported adverse reaction
BRADYCARDIA is the #14 most commonly reported adverse reaction for PROPAFENONE HYDROCHLORIDE, manufactured by Actavis Pharma, Inc.. There are 75 FDA adverse event reports linking PROPAFENONE HYDROCHLORIDE to BRADYCARDIA. This represents approximately 1.6% of all 4,618 adverse event reports for this drug.
Patients taking PROPAFENONE HYDROCHLORIDE who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is a less commonly reported adverse event for PROPAFENONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to bradycardia, the following adverse reactions have been reported for PROPAFENONE HYDROCHLORIDE:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 75 FDA reports for PROPAFENONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 1.6% of all adverse event reports for PROPAFENONE HYDROCHLORIDE, making it a notable side effect.
If you experience bradycardia while taking PROPAFENONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.